Rx Innovation Benefit, Not R&D Cost, Is Strongest Argument For Patents, PTO Director Says
This article was originally published in The Pink Sheet Daily
Executive Summary
PTO Acting Director Dudas says the agency and industry need to work together in combating growing "anti-IP" sentiment across the globe.